Iovance Biotherapeutics, Inc.
IOVA · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | — | — | -398.88M | -395.89M | -2.49 |
| 2023 FY | 1.19M | -9.57M | -460.56M | -444.04M | -1.89 |
| 2024 FY | 164.07M | 40.08M | -395.28M | -372.18M | -1.28 |
| 2025 FY | 263.50M | 256.22M | -403.36M | -390.98M | -1.09 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 663.98M | 164.34M | 231.73M | 85.45M | 499.64M |
| 2023 FY | 780.35M | 195.74M | 114.89M | 75.86M | 584.61M |
| 2024 FY | 910.43M | 200.02M | 115.69M | 58.26M | 710.41M |
| 2025 FY | 913.17M | 214.59M | 163.08M | 48.44M | 698.58M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -292.76M | -20.43M | -313.18M | — | 153.85M |
| 2023 FY | -361.82M | -22.29M | -384.11M | — | -56.84M |
| 2024 FY | -352.98M | -11.07M | -364.05M | — | -59.27M |
| 2025 FY | -302.41M | -33.84M | -336.24M | — | 47.38M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 1.02B | 871.38M | — | — | — |
| 2023 FY | 1.91B | 1.87B | — | — | — |
| 2024 FY | 2.15B | 2.09B | — | — | — |
| 2025 FY | 975.55M | 860.92M | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 59.95M | 3.29M | -113.77M | -111.66M | -0.33 |
| 2025 Q3 | 67.46M | 66.05M | -94.90M | -91.25M | -0.25 |
| 2025 Q4 | 86.77M | 187.30M | -73.46M | -71.90M | -0.15 |
| 2026 Q1 | 71.43M | 70.41M | -81.04M | -79.05M | -0.19 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 907.44M | 208.95M | 132.47M | 53.17M | 698.49M |
| 2025 Q3 | 904.95M | 202.66M | 158.13M | 52.49M | 702.29M |
| 2025 Q4 | 913.17M | 214.59M | 163.08M | 48.44M | 698.58M |
| 2026 Q1 | 925.67M | 203.91M | 196.51M | 47.78M | 721.75M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -67.45M | -7.46M | -74.91M | — | -39.64M |
| 2025 Q3 | -78.70M | -10.84M | -89.55M | — | 25.69M |
| 2025 Q4 | -52.57M | -9.32M | -61.89M | — | 4.96M |
| 2026 Q1 | -72.07M | -6.61M | -78.68M | — | -157.09M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 575.36M | 496.06M | — | — | — |
| 2025 Q3 | 789.96M | 684.32M | — | — | — |
| 2025 Q4 | 1.11B | 996.38M | — | — | — |
| 2026 Q1 | 1.47B | 1.32B | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |